Nostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
Nostrum Laboratories is recalling 7,071 bottles of Metformin Hydrochloride Extended-Release Tablets, 750 mg, because the product contains N-Nitrosodimethylamine (NDMA) above acceptable levels.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves the presence of a known carcinogenic impurity (NDMA) above acceptable levels, which meets the rubric criteria for a Severe rating (FDA Class II with significant health risk).
Plain-English summary
Nostrum Laboratories, Inc. is recalling 7,071 bottles of Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg. The affected product is identified by Lot MET200601 with an expiration date of 07/2022 and NDC 29033-056-01. The recall is due to the detection of the impurity N-Nitrosodimethylamine (NDMA) above the acceptable intake level, which constitutes a Current Good Manufacturing Practice (CGMP) deviation.
The affected tablets were distributed nationwide. This is a prescription-only medication. The FDA has classified this recall as Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Consumers and healthcare providers should stop using the affected product and contact their pharmacist or healthcare provider for a replacement or alternative treatment. Patients should not discontinue their medication without consulting their healthcare provider.
The recalled product
- Product
- Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120. NDC: 29033-056-01
- Manufacturer
- Nostrum Laboratories Inc
- Category
- Drug — Prescription Medication
- Affected units
- 7,071
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot MET200601
- 07/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Nostrum Laboratories Inc
See all →- ModerateSucralfate tablets recalled because bankruptcy left the quality program unmonitored
FDA (Drugs) · 2025-08-06
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- ModerateNostrum Recalls Theophylline Tablets Due to Incorrect Lot and Expiration Dates
FDA (Drugs) · 2020-04-01
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SeverePD-Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SeverePD-Rx Recalls Metformin Hydrochloride Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-11-11